Hydronephrosis Treatment Market – By Type (Unilateral, Bilateral), Indication (Intrinsic, Extrinsic), Diagnosis (Laboratory Test, Imaging), Treatment (Shock Wave Lithotripsy, Laparoscopy, Bladder Catheterization), Age Group & Global Forecast, 2024 – 2032

Hydronephrosis Treatment Market Size

Hydronephrosis Treatment Market size was valued at around USD 2.4 billion in 2023 and is expected to reach around USD 4.9 billion by 2032 at a CAGR of 8.2% during the forecast period. The growing prevalence of kidney diseases is anticipated to be among the primary factor propelling the growth of the market.
 

Hydronephrosis treatment refers to the medical interventions and procedures aimed at managing and resolving the condition of hydronephrosis, which is characterized by the swelling or enlargement of one or both kidneys due to the buildup of urine caused by an obstruction or blockage in the urinary tract.
 

The growing prevalence of kidney diseases, including chronic kidney disease (CKD), is a significant health concern globally. Factors such as diabetes, hypertension, obesity, and family history contribute to the increasing incidence of CKDs. According to the Centers for Disease Control and Prevention (CDC), in 2023, more than 1 in 7 U.S. adults, about 35.5 million people, or 14% are estimated to have CKD. CKD plays a substantial role in the development of end-stage renal disease (ESRD) due to the progressive nature of kidney damage associated with CKDs.
 

For example, in the U.S., the number of reported ESRD cases increased by 41.8% from 2000 to 2019, with the number of prevalent cases approximately doubling during this period, according to the CDC. These statistics underscores the growing burden of kidney diseases globally and emphasize the need for increased awareness, early detection, and effective management strategies to address this public health issue.
 

Hydronephrosis Treatment Market Trends

Increasing adoption of advanced medical imaging techniques for diagnosis is anticipated to propel the market growth over the analysis period. Adoption of MRI and CT scans for diagnostic procedures is significantly impacting medical practices globally.
 

• Advanced imaging techniques, such as Magnetic Resonance Urography (MRU), offer significant advantages in the diagnosis and treatment of hydronephrosis. MRU has been shown to have high sensitivity and specificity for detecting and grading hydronephrosis, as well as identifying the location of obstruction when present. This accuracy makes MRU a valuable tool in diagnosing and monitoring hydronephrosis.
   
• Additionally, CT scans with special dose-reduced protocols are increasingly gaining importance in detecting calcified stones. By applying dose reduction algorithms, the effective radiation dose can be significantly reduced, making it safer for patients while maintaining diagnostic accuracy. Due to such advantages the need for diagnosis procedures for hydronephrosis is rising.
   

Hydronephrosis Treatment Market Analysis

Based on type, the market is segmented into unilateral hydronephrosis and bilateral hydronephrosis. The unilateral hydronephrosis segment held leading revenue share in 2023 and is anticipated to reach over USD 2.9 billion by 2032.
 

• Structural abnormalities in the urinary tract, such as ureteropelvic junction (UPJ) obstruction or ureteral strictures, can lead to unilateral hydronephrosis. The prevalence of such abnormalities contributes to the rising demand for treatment in this segment.  
   
• Moreover, variations in healthcare provider practices, including diagnostic approaches, treatment protocols, and follow-up care, may impact the demand for treatment in the unilateral hydronephrosis segment.

Based on indications, the hydronephrosis treatment market is segmented into intrinsic and extrinsic. The intrinsic segment held leading revenue share in 2023 and is anticipated to reach USD 3.4 billion by 2032.
 

• Conditions such as kidney stones, urinary tract infections (UTIs), benign prostatic hyperplasia (BPH), pelvic tumors, and congenital abnormalities are common underlying causes of hydronephrosis. The growing incidence of these conditions contributes to the segmental growth.
   
• Moreover, sedentary lifestyles, poor dietary habits, and increased consumption of processed foods contribute to the development of conditions such as kidney stones and urinary tract infections. Lifestyle factors plays a significant role in driving the incidence of hydronephrosis-related conditions, thus, driving the industry growth.  
   

Based on diagnosis, the hydronephrosis treatment market is segmented into laboratory tests and imaging. The imaging segment held leading revenue share in 2023 and was valued at USD 1.4 billion.
 

• Imaging techniques are generally non-invasive, making them preferred options for diagnosing hydronephrosis, especially in pediatric and geriatric populations or individuals with comorbidities who may be at increased risk from invasive procedure. 
   
• Moreover, patients often prefer non-invasive imaging techniques due to their comfort and convenience compared to invasive procedures. This preference drives the demand for imaging modalities in the diagnosis and management of hydronephrosis.
   

Based on treatment, the hydronephrosis treatment market is segmented into shock wave lithotripsy, laparoscopy, bladder catheterization, steroid therapy, other treatments. The shock wave lithotripsy segment held leading revenue share of around 34.9% in 2023 and is anticipated to witness robust growth.
 

• Compared to surgical procedures such as ureteroscopy or percutaneous nephrolithotomy (PCNL), SWL typically involves minimal discomfort and has a shorter recovery time. Patients can often resume normal activities shortly after the procedure, leading to increased patient satisfaction and demand.
   
• The global incidence of kidney stones is increasing, driven by factors such as dietary habits, dehydration, obesity, and metabolic disorders. As the incidence of kidney stones rises, so does the demand for effective treatment options like SWL.
   

The hydronephrosis treatment market by age-group is categorized into adult and pediatric. The pediatric segment held significant market share in 2023 and is expected to reach around USD 1.2 billion by 2032.
 

• Many cases of pediatric hydronephrosis are congenital, meaning they are present at birth due to structural abnormalities or urinary tract malformations. The prevalence of congenital hydronephrosis contributes to the segment growth.
   
• Moreover, advances in prenatal imaging techniques and widespread adoption of prenatal screening programs allow for early detection of hydronephrosis during pregnancy. Prenatal diagnosis enables timely intervention and treatment planning, thereby, increasing the demand for pediatric treatment options.

North America hydronephrosis treatment market accounted for around USD 1 Billion revenue in 2023 and is predicted to witness substantial market growth.
 

• North America has well-developed healthcare infrastructure, including modern hospitals, specialized clinics, and advanced diagnostic and treatment facilities. Access to state-of-the-art medical technology and expertise enhances the diagnosis and management of hydronephrosis, contributing to increased demand for treatment.
   
• Furthermore, obesity and diabetes are significant risk factors for the development of kidney stones and other urinary tract conditions. North America has a high prevalence of obesity and diabetes, contributing to the increased incidence of hydronephrosis, thus, driving the demand for treatment.
   

Hydronephrosis Treatment Market Share

The hydronephrosis treatment industry is competitive in nature, with several large multinationals and small and mid-sized companies competing in the industry. The development and launch of novel advanced products based on different technologies is among a key market strategy.
 

Hydronephrosis Treatment Market Companies

Some of the eminent market participants operating in the hydronephrosis treatment industry include:

• AbbVie Inc
• Amgen Inc
• The Anthem Group
• F. Hoffmann-La Roche Ltd
• Nephrogenex Inc.    
• Novartis AG
• Pfizer Inc.
• Phraxis Inc.
• Renal Associates P.A.
• Sanofi
   

Hydronephrosis Treatment Industry News:

• In June 2023, Novartis AG bolstered its innovative medicines strategy and renal pipeline by acquiring Chinook Therapeutics. This acquisition may expand the company’s drug portfolio to target kidney disease treatment.  
   

Hydronephrosis treatment market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2018 – 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Type

• Unilateral hydronephrosis
• Bilateral hydronephrosis

Market, By Indication

• Intrinsic
  • Acute unilateral obstructive uropathy
  • Kidney stone
  • Bladder cancer
  • Bladder stones
  • Urethral stricture
  • Pelvic organ prolapse
  •  Other intrinsic indications
• Extrinsic
  • Retroperitoneal fibrosis
  • Ovarian vein syndrome
  • Other extrinsic indications

Market, By Diagnosis

• Laboratory tests
  • Urinalysis
  • Complete blood count
  • Electrolyte analysis
  • Other laboratory tests
• Imaging
  • Ultrasound
  • Intravenous pyelography
  • KUB X-Rays
  • CT-scan
  • Other imaging types

Market, By Treatment

• Shock wave lithotripsy
• Laparoscopy
• Bladder catheterization
• Steroid therapy
• Other treatment types

Market, By Age Group

• Adult
• Pediatric

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Middle East and Africa
  • Saudi Arabia
  • South Africa
  • UAE
  • Rest of Middle East and Africa